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ABSTRACT 
Objectives: Objective of our present study was to develop a novel ultra fast liquid chromatographic method for quantitative simultaneous 
estimation of Clopidogrel, Pantoprazole & Rosuvastatin in human plasma and to validate the developed method following USFDA guidelines. 
Methods: In the current study, the analysis was performed on phenomenex C8 (250 × 4.6 mm, 5μm) column using phosphate buffer (pH-2.5) and 
acetonitrile (45: 55 v/v) as mobile phase at flow rate of 1.2 mL/min. The system consisted of a pump (Shimadzu, prominence, UFLC), with 20 µl 
sample injector, along with a PDA detector at a wavelength of 254, 243 nm and 220 nm 
Results: In this developed method Clopidogrel, Pantoprazole & Rosuvastatin, eluted at a retention time of 2.566, 5.002 and 9.301 min respectively. 
The proposed method is having linearity in the concentration range from 5 to 50μg/mL of Clopidogrel, Pantoprazole & Rosuvastatin. The current 
method was validated with respect to accuracy, linearity; precision, lowest limit of quantification (LLOQ) and recovery according to the USFDA 
guidelines.  A good linear relationship over the concentration range of 5-50µg/ml was shown. Validation of the method was carried out as per the 
USFDA draft guidelines. 
for Clopidogrel, Pantoprazole and Rosuvastatin respectively. 
Data was compiled using Shimadzu LC Solution software. 
Conclusion: A novel specific, accurate, precise UFLC method was developed for quantitative simultaneous estimation of Clopidogrel, Pantoprazole 
& Rosuvastatin in human plasma and validated. The developed method is suitable and economic for routine analysis and pharmacokinetic studies of 
Clopidogrel, Pantoprazole & Rosuvastatin simultaneously. The method developed was found to be precise, accurate, specific, linear and sensitive. 
Statistical analysis shows that the method is reproducible and selective for the estimation of Clopidogrel, Pantoprazole & Rosuvastatin in dosage 
form of patient plasma.  
Keywords: Bioanalytical, Clopidogrel, Pantoprazole & Rosuvastatin, RP-UFLC, USFDA. 
 
INTRODUCTION 
Clopidogrel, (CPG) (+)-(S)-methyl 2-(2-chlorophenyl)-2-(6, 7-
dihydrothieno [3, 2-c] pyridin-5(4H)-yl) acetate (Fig. 1A) is a 
prodrug that is converted in the liver to an active thiol metabolite, 
which irreversibly inhibits the platelet P2Y12 adenosine 
diphosphate receptor. This bioactivation is mediated by hepatic 
cytochrome P450 isoenzymes, with cytochrome P450 2C19 playing 
a major role. The cytochrome P450 (CYP) superfamily of heme 
enzymes plays an important role in the metabolism of a large 
number of endogenous and exogenous compounds, including most 
of the drugs currently on the market. Inhibitors of CYP enzymes 
have important roles in the treatment of several disease conditions 
such as numerous cancers and fungal infections in addition to their 
critical role in drug-drug interactions. Given the important role of 
cytochrome P450 2C19 in the bioactivation of Clopidogrel, 
Pantoprazole & Rosuvastatin, drugs that inhibit this enzyme may 
reduce the antiplatelet effect of Clopidogrel. It is used in the 
prevention of vascular ischemic events in patients with symptomatic 
atherosclerosis, acute coronary syndrome without ST-segment 
elevation (NSTEMI), ST elevation MI (STEMI).  
Pantoprazole, (RS)-6-(Difluoromethoxy)-2-[(3, 4-dimethoxypyridin-
2-yl) methylsulfinyl]-1H-benzo[d] imidazole (Fig. 1B) is a proton 
pump inhibitor drug that inhibits gastric acid secretion. 
Pantoprazole is metabolized in the liver by the cytochrome P450 
system. Metabolism mainly consists of demethylation by CYP2C19 
followed by sulfation. Another metabolic pathway is oxidation by 
CYP3A4. Pantoprazole metabolites are not thought to have any 
pharmacological significance. Generally inactive at acidic pH of the 
stomach, thus it is usually given with a pro kinetic drug. 
Pantoprazole binds irreversibly to H+K+ATPase (Proton pumps) and 
suppresses the secretion of acid. As it binds irreversibly to the 
pumps, new pumps have to be made before acid production could be 
resumed. The drug's plasma half-life is about 2 hours. Pantoprazole 
is used for short-term treatment of erosion and ulceration of the 
esophagus caused by gastroesophageal reflux disease. Initial 
treatment is generally of eight weeks' duration, after which another 
eight week course of treatment may be considered if necessary. It 
can be used as a maintenance therapy for long term use after initial 
response is obtained. Rosuvastatin, (3R, 5S, 6E)-7-[4-(4-
fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl) 
pyrimidin-5-yl]-3, 5-dihydroxyhept-6-enoic acid (Fig. 1C) is a 3-
hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor, or statin, 
that has been developed for the treatment of dyslipidemia, 
atherosclerosis, high cholesterol, hyperlipoproteinemia, elevated 
LDL, Prevention of Cardiovascular Disease. 
Rosuvastatin, a new statin, has been shown to possess a number of 
advantageous pharmacological properties, including enhanced 
HMG-CoA reductase binding characteristics, relative hydrophilicity, 
and selective uptake activity in hepatic cells. Cytochrome p450 
(CYP) metabolism of Rosuvastatin appears to be principally 
mediated by the 2C9 enzyme, with little involvement of 3A4; this 
finding is consistent with the absence of clinically significant 
pharmacokinetic drug-drug interactions between Rosuvastatin, 
Clopidogrel & Pantoprazole known to inhibit CYP enzymes. 
Literature survey reveals that few analytical methods have been 
reported for Clopidogrel, Pantoprazole & Rosuvastatin including RP-
HPLC methods [1-4], HPTLC method [5, 6], UV method [7], normal 
phase HPLC [8], GC method [9], LC-MS method [10], capillary 
electrophoresis method [11].  
Studies have shown that genetic polymorphisms in the hepatic 
cytochrome P450 (CYP2C19) influence the antiplatelet effects of 
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Clopidogrel. Moreover the same cytochrome partially metabolizes 
Rosuvastatin. 
 
Fig. 1(A): Structure of Clopidogrel 
 
Literature survey reveals that few analytical methods 
have been reported for Rosuvastatin include has been estimated by 
colorimetry [12], Spectrophotometric methods [13, 14], LC-MS/MS 
[15], RP-HPLC [16-21]. 
 
 
Fig. 1(B): Structure of Pantoprazole 
 
 
Fig. 1(C): Structure of Rosuvastatin 
MATERIALS AND METHODS 
Chemical and Reagents 
Samples of Clopidogrel, Pantoprazole & Rosuvastatin were received 
from Wintac Limited
Milli-Q-water was used throughout the process, methanol, 
acetonitrile of HPLC grade were procured from Merck Chemical 
Laboratories, Bangalore, India. 
, Bangalore, Karnataka, India. The human 
plasma was received from JSS Hospital, Mysore, Karnataka, India. All 
the chemicals and reagents used were of analytical grade only.  
Instrumentation 
The present study was carried out on UFLC (SHIMADZU) equipped 
with LC solution software with PDA detector. Separation was 
attained using phenomenex C8 column.  
The mobile phase was a mixture of potassium dihydrogen 
orthophosphate buffer (pH-2.5) and acetonitrile (45:55 v/v) at flow 
rate 1.2 mL/min. The contents of mobile phase were filtered before 
use through membrane filter (0.45 μ). The optimized 
chromatographic conditions are shown in Table 1. 
Preparation of Mobile Phase 
Mobile phase is prepared by adding 4.08g potassium dihydrogen 
orthophosphate in 250 ml of Millipore water, dissolve and adjust the 
pH to 2.5 using ortho phosphoric acid and made upto 1000 ml 
(0.03M) using Millipore water. Potassium dihydrogen 
orthophosphate buffer and acetonitrile in the ratio of 45: 55 (v/v). 
Preparation of Standard Solutions 
Stock solution of Clopidogrel, Pantoprazole & Rosuvastatin were 
prepared by dissolving 10 mg of drugs Clopidogrel, Pantoprazole & 
Rosuvastatin in 50 ml of methanol in 100 ml volumetric flask 
dissolved and volume was made up to 100 ml using the methanol to 
get the standard stock solutions of concentration 0.1 mg/mL (100 
μg/ml) for Clopidogrel, Pantoprazole & Rosuvastatin. Different 
working standard solutions were prepared from the above solution. 
 
Table 1: Optimized Chromatographic conditions 
Chromatographic Conditions: 
Column C8 (250 x 4.6 mm. 5 μ) phenomenex 
Flow rate 1.2 mL/min 
Run time 10 min 
Wavelength 254, 243 nm and 220 nm for Clopidogrel, Pantoprazole & Rosuvastatin respectively 
Injection Volume 20μL 
Detector PDA Detector 
Elution Isocratic 
Mobile Phase potassium dihydrogen orthophosphate buffer (pH-2.5) and acetonitrile (45:55 v/v) 
Column oven temperature 25 ± 5ºC 
 
Method Development 
Selection of mobile phase  
Mobile phases were tried in various ratios for selection of solvents of the 
desired polarity. The drugs Clopidogrel, Pantoprazole & Rosuvastatin 
were injected with different mobile phases at different ratios and flow 
rates till a sharp peak, without any interference was obtained. The 
mobile phase selected with good resolution was phosphate buffer (pH 
2.5), and acetonitrile in the ratio 45:55(v/v) (Fig 2).  
Stock and standard solution  
The stock solution of Clopidogrel, Pantoprazole & Rosuvastatin were 
prepared by dissolving 10mg of each drug separately into methanol 
and volume was made up to 100 ml with same solvent. From stock 
solutions (100 μg/ml of each) 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 
μg/ml concentration were prepared separately using methanol as 
solvent. Equal volumes of all the three drugs concentrations were 
mixed and used as standard solutions. 
 
Fig. 2: Chromatogram for Simultaneous estimation of 
Clopidogrel, Pantoprazole and Rosuvastatin (50µg/ml) 
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Preparation of Calibration Curve 
From the stock solution (100 μg/mL) aliquots of Clopidogrel, 
Pantoprazole & Rosuvastatin were pipette into a series of 10 mL 
volumetric flask. The final volume was made up to the mark by using 
HPLC grade methanol. 20μL solution was injected to the column and 
peak areas were measured and the calibration curve was obtained. 
Linear correlations were found between peak ratios of Clopidogrel, 
Pantoprazole & Rosuvastatin and are described by regression 
equation. The Beer’s law was obeyed in the concentration range of 5 
– 50 μg/mL (Figure 3). 
 
 
Fig. 3: Standard calibration graph of Clopidogrel, Pantoprazole 
and Rosuvastatin 
The regression parameters and system suitability of the method 
were shown in Table 2. 
Determination of drugs in plasma (spiking method)  
0.1 ml of drug is added to 0.1 ml of plasma(obtained by centrifuging 
the blood samples at 10,000 rpm for 10 minutes) in appendroff 
tubes and made upto the volume(1.8 ml) with acetonitrile for the 
precipitation of proteins. It is further centrifuged at 10,000 rpm for 
10 minutes. Supernatant fluid is decanted into vial by filtering with 
syringe filters of 0.45μ size. 
The obtained chromatograms are shown in Figure 4. 
 
 
Fig. 4(A): Chromatogram of Blank. 
 
Table 2: The regression and System suitability parameters of the method 
Parameter Clopidogrel Pantoprazole Rosuvastatin 
Linearity (µg/ml) 5-50 5-50 5-50 
Regression Equation 21909x + 106284 13290x + 35691 19969x + 79109 
Regression coefficient (R2) 0.994 0.9924 0.9973 
Slope 97774 85001 85001 
Intercept 458786 583384 583384 
Retention Time (Rt) 2.566 5.002 9.301 
LLOQ (µg/ml) 5.193  5.264  5.920 
Resolution (RS) 2.58 2.33 2.63 
Capacity Factor (K) 2.76 3.06 2.11 
Tailing Factor (T) 1.037 1.265 1.61 
Theoretical Plates 3486 5401 3942 
 
 
Fig. 4(B): Chromatogram of Clopidogrel & Pantoprazole, 
 
Protein precipitation 
The protein precipitation method was used for extraction of 
Clopidogrel, Pantoprazole and Rosuvastatin from plasma 
individually using acetonitrile as protein precipitant. 100 μL of blank 
plasma was spiked with 100.0 μL of standard Clopidogrel, 
Pantoprazole and Rosuvastatin from 100 μg/mL dilution of 
Clopidogrel, Pantoprazole and Rosuvastatin separately. This spiked 
plasma was vortexed for 2 min. 
 
Fig. 4(C): Chromatogram of Clopidogrel & Rosuvastatin, 
 
The mixture was further vortexed for 2 min and centrifuged at 
10000 rpm for 10 min. After centrifugation, 100 µL of the 
supernatant was collected and 100 µL of Internal Standard 
nimesulide was added of required concentration and diluted to 1.0 
mL with acetonitrile. A 20.0 µL aliquot of final preparation was 
injected into the HPLC system. 
Nagavi et al. 




Fig. 4(D): Chromatogram of  Clopidogrel, Pantoprazole & 
Rosuvastatin in plasma. 
 
RESULTS AND DISCUSSION 
Method validation 
Since the UFLC method was developed, validation of the method by 
using various parameters was performed to ensure that the 
accomplishment of the method meets the requirements of the 
described bioanalytical applications. Following parameters were 
performed for method validation:  
1. System suitability 
2. Specificity  




System suitability parameters 
The system suitability parameters such as asymmetric factor, tailing 
factor, theoretical plates and plate numbers were measured. The 
values found for these parameters are described in Table 3. All the 
system suitability parameters found to be according to the 
acceptable limits of the bio -analytical methods. 
Linearity 
From the experimental conditions described above, linear 
calibration curves of Clopidogrel, Pantoprazole & Rosuvastatin were 
obtained for ten different concentrations level for both. The r2 for 
Clopidogrel was 0.994 and for Rosuvastatin was 0.9973.  
Linear correlations were found between peak area of Clopidogrel, 
Pantoprazole & Rosuvastatin concentration and are described by the 
regression equation. The linearity range for Clopidogrel, 
Pantoprazole & Rosuvastatin is 10-50 μg/ml. Results are specified in 
Table 2. 
Specificity 
Specificity is the capability to evaluate the analyte distinctly in the 
presence of expected impurities and degraded products. 
20 µl of the blank was injected in duplicate to the UPLC system and 
chromatographed. 
20 µl of Clopidogrel, Pantoprazole & Rosuvastatin standard 
solutions were injected in duplicate to the UPLC system. Standard 
chromatograms obtained are presented in Fig 5 (A, B, C and D). 
  
Table 3: System suitability parameters of bio-analytical method 
Parameters 
 
Results Acceptable limits 
Clopidogrel IS Pantoprazole IS Rosuvastatin IS 
Asymmetry 1.02 0.99 1.09 0.97 1.22 0.97 < 1.5 
Tailing Factor 1.037 1.032 1.265 1.201 1.61 1.54 < 2 
Plate no. 3486 3393 5401 5011 3942 3301 > 2000 
Resolution 2.58 1.98 2.33 2.01 2.63 1.80 > 1.5 
Capacity factor 2.76 2.12 3.06 2.09 2.11 2.22 > 2 
 
 
Fig. 5(A): Chromatogram of Blank, 
 
Fig. 5(B): Chromatogram of Standard solution of Clopidogrel 
(50µg/ml), 
 
Fig. 5(C): Chromatogram of  Standard solution of Pantoprazole 
 
Fig. 5(D): Chromatogram of Standard solution of Rosuvastatin 
(50µg/ml). 
Nagavi et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 9, 490-496 
494 
 
Precision and accuracy  
The accuracy of an bioanalytical method is the percentage of 
relativeness between the conventional true value and the value 
obtained by that method. 
Accuracy is determined by replicate analysis of samples containing 
known amounts of the analyte. Accuracy was measured using a 
minimum of five determinations per concentration. The mean value 
was found to be within 20% of the actual value except at LLOQ, 
where it should not deviate by more than 25%.  
The precision was measured using a minimum of five 
determinations per concentration. The precision determined at each 
concentration level did not exceed 20% of the CV except for the 
LLOQ, where it should not exceed 25% of the CV.  
Precision was further subdivided into within-run and between-run 
precision. Within-run (also known as intra-batch precision or 
repeatability) is an assessment of the precision during a single 
analytical run. Between-run precision (also known as inter batch 
precision or repeatability), is a measurement of the precision with 
time, and may involve different analysts, equipment, reagents, and 
laboratories. Samples with concentrations over the ULOQ were 
diluted with the same matrix as used for the study samples, and 
accuracy and precision was determined. 
The Within-run precision and accuracy of the method for 
Clopidogrel, Pantoprazole & Rosuvastatin are presented in (Table 
4A). The Between-run precision and accuracy of the method for 
Clopidogrel, Pantoprazole & Rosuvastatin are presented in (Table 
4B). All values for accuracy and precision were within the 
recommended limits. 
 
Table 4: Within-run and Between-run Precision of Clopidogrel, Pantoprazole & Rosuvastatin 
(A) Within-run Precision 
Concentration 
(µg/ml) 
Mean (µg/ml) %RSD 
Clopidogrel Pantoprazole Rosuvastatin Clopidogrel Pantoprazole Rosuvastatin 
Low (n=3) 5 5.21 5.26 5.25 0.06 0.03 0.07 
Medium (n=3) 30 30.11 29.98 30.6 0.07 0.05 0.08 
High (n=3) 50 49.30 50.30 50.16 0.06 0.09 0.07 
(B) Between-run Precision 
Concentration 
(µg/ml) 
Mean (µg/ml) %RSD 
Clopidogrel Pantoprazole Rosuvastatin Clopidogrel Pantoprazole Rosuvastatin 
Low (n=3) 5.12 5.44 5.30 0.06 0.10 0.08 
Medium (n=3) 30.7 29.92 30.16 0.07 0.08 0.05 
High (n=3) 49.21 50.19 50.35 0.05 0.03 0.06 
 
Table 5: Percent recovery studies of Clopidogrel, Pantoprazole & Rosuvastatin and Rosuvastatin. 
Level Concentration 
(µg/ml) 
%Recovery of Clopidogrel %Recovery of Pantoprazole %Recovery of Rosuvastatin 
Low 5 97.6 98.1 96.8 
Medium 30 98.2 97.0 98.4 
High 50 96.7 97.9 98.2 
 
Table 6: Freeze Thaw Stability of Clopidogrel, Pantoprazole & Rosuvastatin 
Level/ Time (hr) Clopidogrel (%RSD) Pantoprazole (%RSD) Rosuvastatin (%RSD) 
0  3  6  12  24  0  3  6  12  24  0  3  6  12  24  
LQC 3.54 2.18 3.46 2.97 2.41 5.01 3.44 2.01 3.91 2.21 3.90 2.91 2.68 4.03 3.90 
MQC 2.84 3.26 4.19 2.99  2.75 5.55 2.11 3.04 3.98 3.00 3.66 4.01 4.81 5.20 3.90 
HQC 3.39 2.88 3.41 2.04 2.94 6.10 5.11 2.05 2.99 1.94 5.21 4.99 5.01 5.66 4.91 
 
Table 7: Summary of validation parameters data for Clopidogrel, Pantoprazole & Rosuvastatin 
Parameters Clopidogrel Pantoprazole Rosuvastatin Acceptance criteria 
Retention Time (min) 2.566 5.002 9.301 - 
LLOQ (μg/ml) 5.193 5.264 5.920 - 
Linearity (μg/ml) 5-50 5 - 50 5-50 - 
Accuracy (% Recovery) 96.7-98.2% 97.0 – 98.1 96.8-98.2 80 -120% 
Precision (%RSD) Within-run 0.065 0.060 0.075 < 2% 
Between-run 0.060 0.070 0.065 
Specificity No peak of diluent, excipients and impurities were detected. No peak should 
be detected 
 
System Suitability Parameters 
 
N 4573.51 5903.52 7923.79 >2000 
HETP 81.0 88.0 90.0 - 




Recovery of the method was performed comparing the three quality 
control (QC) samples at low, medium and high concentrations (5, 30, 
50 μg/ml) The recoveries of Clopidogrel, Pantoprazole & 
Rosuvastatin and Rosuvastatin were determined by comparing peak 
area obtained for QC samples that were subjected to the extraction 
procedure with those obtained from blank plasma extracts that were 
spiked post extraction to the same nominal concentrations. The 
results obtained from the proposed method are recorded in Table 5. 
Stability studies  
The stability in human plasma over three freeze–thaw cycles and 
during short-term, long-term, and post-preparative storage was 
tested by analysis of LQC and HQC samples. The freeze–thaw 
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stability was determined over three freeze–thaw cycles within 3 
days. Spiked plasma samples were frozen at -22oC for 24 h and 
thawed at room temperature in each freeze–thaw cycle. To study 
short-term stability, the frozen (-22oC) and then thawed plasma 
samples were kept at room temperature for 6 h before sample 
preparation. The results obtained from these test samples were 
compared with those from freshly thawed and processed samples 
(reference samples). Long-term stability was determined after 
keeping spiked plasma samples frozen at -22oC for 1 month. For this 
stability test the samples (test samples) were analyzed and the 
results were compared with those obtained from freshly prepared 
and processed samples (reference samples). The stability in stock 
solutions was studied after storage at 2oC for 1 month. The results 
obtained from assessment of stability are given in Table 6. Three 
freeze–thaw cycles of the quality control samples did not seem to 
affect quantification. Quality-control samples stored in a freezer at -
22oC were stable for at least 1 month. Thawing of the frozen 
samples and keeping them at room temperature for 6 h had no effect 
on quantification. The stability in stock solutions was confirmed 
after storage for 29 days at 2oC. 
CONCLUSION 
The developed and validated method involves simple and precise 
method for bioanalytical determination of Clopidogrel, Pantoprazole 
& Rosuvastatin in human plasma. This study showed that 
Clopidogrel along with Pantoprazole & Rosuvastatin significantly 
decreased plasma level of Clopidogrel.  Such a variation would lead 
to sub therapeutic concentration and a consequent lack of 
therapeutic efficacy of Clopidogrel. This consequence may be 
expected due to inhibition of enzyme cytochrome P450 2C19 which 
is responsible for bioactivation of Clopidogrel. In conclusion, present 
study showed that Pantoprazole and Rosuvastatin can alter the 
pharmacokinetics of Clopidogrel to significant levels.  Summary of 
validation parameters data for Clopidogrel, Pantoprazole & 
Rosuvastatin is presented in table 7. 
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